Study:
Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma
Rationale:
n/a
Purpose:
As Conditions of Approval of the PMA for the Alair System, the FDA requires Asthmatx to
generate data to assess the durability of the BT treatment effect as well as safety data in
the intended use population in the United States.
Study Status: Recruiting
Recruiting:
Joanne Baran-Smiley, RN, BSN 216-445-7706 baranj2@ccf.org
| Condition |
Intervention |
Phase |
|
Severe Asthma |
Device: Alair System |
Phase 4 |
Verified by
Asthmatx, Inc.
January, 2013
Sponsored by: Asthmatx, Inc.
Information provided by: Asthmatx, Inc.
ClinicalTrials.gov identifier: NCT01350336
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
n/a